PHARMA COGENITICALLY PERSONALIZED CHEMOTERAPY: MARKERS PREDICTING THE TOXICITY OF ANTITUMOR MEDICINES IN BREAST CANCER

Pulatov D. A.*, Avezmuratova G. A., Dolimova D. A. and Turdikulova Sh.U.

ABSTRACT

Conclusion аccording to the results of studies by foreign scientists, the Lys751Gln polymorphism of the XPD gene [7, 8, 22] was associated with cancer of the head and neck organs, oncopathology of the abdominal and lung organs. The results of this study confirmed the fact that this gene cannot be selected as a marker when choosing chemotherapy methods. IVS14 + 1G> A and D949V polymorphisms, according to foreign scientists, have a high degree of association, both of gastric cancer and breast cancer and collar {20,23]. In contrast to this data, our study showed that D949V mutation is not found in the DPD gene in patients of the population of Uzbekistan. However, the frequency of occurrence of a heterozygous and homozygous polymorphism of 1VS14 + 1G> A in the DPYD gene was extremely high in this population. This polymorphism may be an important clinical and genetic factor for the individual choice of an adequate regimen with the 5-fluorourant preparation for further treatment of patients. suffering from breast cancer.

Keywords: Pharmacogenetics, personalized, predictive factors, chemotherapy, toxicity.